Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Journal of Research in Pharmacy 2019 , Vol 23 , Issue 4
The ameliorating effect of silymarin against vancomycin-induced apoptosis and inflammation in rat liver
Sevda GÜZEL1,Zuhal UÇKUN ŞAHİNOĞULLARI2,Necmiye CANACANKATAN3,Şerife Efsun ANTMEN4,Deniz KİBAR5,Gülsen BAYRAK5
1Department of Pharmacognosy, Faculty of Pharmacy, Mersin University, Mersin, Turkey
2Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Mersin University, Mersin, Turkey
3Department of Biochemistry, Faculty of Pharmacy, Mersin University, Mersin, Turkey
4Vocational School of Medical Services, Mersin University, Mersin, Turkey
5Department of Histology and Embryology, Faculty of Medicine, Mersin University, Mersin, Turkey
DOI : 10.12991/jrp.2019.181 Silymarin (SL), a flavonolignan complex isolated from seeds of Silybum marianum (Asteraceae), is known for its hepatoprotective, anti-apoptotic, anti-inflammatory, and antioxidant activities. A glycopeptide antibiotic, Vancomycin (VA) which is used for the treatment of serious infections caused by multi-resistant Gram-positive microorganisms has been clinically used for a long time. The aim of the present study was to evaluate potential therapeutic efficiency of SL against VA-induced apoptosis and inflammation using apoptotic (caspase-3, -8, and, -9 enzyme activities) and inflammatory (Tumor necrosis factor-alpha (TNF-α)) markers, and histopathological examinations in rat liver. A total of 49 male Wistar albino rats was divided into 7 groups including control (saline, intraperitoneally (i.p.)), Dimethyl sulfoxide (i.p.), VA (400 mg/kg/day, i.p.), SL100 (100 mg/kg/day, i.p.), VA+SL50 (50 mg/kg/day, i.p.), VA+SL100 (100 mg/kg/day, i.p.), and VA+SL200 (200 mg/kg/day, i.p.). SL was administered once a daily for 8 days. One day after the first treatment of SL, VA administration was started and continued for 7 days. Hepatic TNF-α levels were evaluated by ELISA and hepatic caspase activities were evaluated according to the colorimetric method. Significantly increased caspase activities were determined in VA group compared to control group (P<0.05). However, significantly reduced caspase activities were determined in VA+SL200 group when compared to VA group (P<0.05). TNF-α level in VA group was found to be statistically higher than control group (P<0.05). TNF-α levels of SL100, VA+SL (50, 100, and 200) groups were significantly lower than VA group (P<0.05). VA+SL200 group was found to be the most effective group according to reducing caspase activities and TNF-α level. Keywords : Caspase; hepatoprotective; histopathology; silymarin; TNF-α
Marmara University